Peptide Chemistry
Peptide library and custom synthesis capabilities spanning linear, cyclic and modified peptides and various peptide-based conjugates.
A dedicated 1,500 m² peptide R&D synthesis center is supported by a team of 100+ experienced chemists and top-class equipment, with 20,000+ peptides delivered every year.
AI-Enabled Discovery
AI-assisted virtual screening and computational design tools help prioritize promising candidates before synthesis, enabling efficient exploration of large peptide libraries and focusing resources on compounds with desirable developability characteristics.
AI and Automation Driven Phage Display
The automation-driven phage display platform through our strategic partner Deep Wave, integrates synthetic library design, high-throughput screening, and in vivo mutagenesis to accelerate the discovery of nanobodies and cyclic peptides. Unlike traditional approaches that rely on animal immunization, our customizable synthetic libraries enable direct selection against targets of interest while providing greater control over library composition and screening strategies.
The platform supports parallel screening across multiple targets, enabling efficient interrogation of diverse sequence space and rapid identification of candidate binders. In vivo mutagenesis further expands sequence diversity and supports iterative optimization, improving the probability of identifying high-quality hits. Combined with automated screening workflows and AI-enabled data analysis, the platform is designed to shorten discovery timelines and efficiently advance promising binders toward downstream development.
- Yeast Display: AHEAD-based high-throughput screening and evolution enables rapid discovery and affinity maturation of nanobodies and functional cyclic peptides.
- mRNA Display: it enables high-diversity screening of nanobodies and cyclic peptides, providing a powerful approach for identifying high-affinity binders against challenging targets. With library diversity of up to 10¹³ variants, the platform enables broad exploration of sequence space while requiring only minimal amounts of antigen for screening.
The platform also supports the incorporation of noncanonical amino acids, expanding the chemical diversity and functional properties of peptides beyond the 20 genetically encoded amino acids. This flexibility enables the discovery of novel binders with enhanced affinity, selectivity, stability, and other desirable properties.
- PANCE (Phage-Assisted Non-Continuous Evolution) platform: it enables rapid, in vivo evolution of nanobodies and cyclic peptides without the need for purified antigen or animal immunization. By using customizable in vivo selection circuits, PANCE directly links the activity of candidate binders to their propagation, enabling efficient enrichment and evolution of molecules with improved functional properties.
The platform leverages in vivo mutagenesis to continuously generate sequence diversity and improve hit rates, accelerating the optimization of promising candidates. With the ability to conduct parallel evolution across multiple targets, PANCE provides a flexible and scalable approach for rapidly evolving binders toward improved affinity, specificity, and performance.
Direct-to-Biology
Our direct-to-biology (D2B) approach enables crude peptides synthesized in parallel and directly tested in functional assays to accelerate hit validation and prioritization.
Where D2B adds value?
- 50+ faster turnaround vs. traditional synthesis
- 70%+ cost reduction per peptide
- High execution reliability at scale 80 – 90% synthesis success rate for both linear and cyclic peptides
Hundreds of peptides synthesized per week
Automated parallel synthesis workflows
Support for linear, cyclic, and macrocyclic peptides
Discovery through scale-up capabilities
